BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

The click-baity headlines surrounding Ozempic, including “the skinny jab” and “Hollywood's best-kept secret”, came thick and ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings also took into consideration ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...